Cognito Therapeutics Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures

May 9, 2022 12:00 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced it has joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measures Development Project to support the advancement of its late-stage disease-modifying therapeutics pipeline for neurodegenerative diseases. The company joins other DiMe partners including Biogen, Eli Lilly, Eisai, Alzheimer's Drug Discovery Foundation (ADDF), and many others.

Founded in 2019, DiMe is the first organization to convene experts from all disciplines comprising the diverse field of digital medicine. The organization’s mission is to advance the safe, effective, equitable, and ethical use of digital medicine to optimize human health.

“Cognito is well-positioned to be an industry leader in this new convergent industry of technology and biotech. We will be launching the world’s first multi-study late-stage clinical program evaluating our novel optogenetics-based therapeutic in patients with MCI and mild-to-moderate Alzheimer’s disease this year,” said Brent Vaughan, CEO, Cognito Therapeutics. “As the leading clinical-stage platform that merges biotech and tech in Alzheimer’s, we look forward to working with DiMe to advance the body of evidence and regulatory paradigm around digital clinical measures.”

“We are thrilled that Cognito is joining our consortium of leading experts to build consensus for a set of core digital clinical measures in ADRD.,” said Christina Marasco, Program Lead, DiMe. “Together, this collaboration will define global meaningful aspects of health at the intersection of technological capabilities, patients, care-partners, and clinical need.”

About Cognito Therapeutics

Cognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic platform has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation treatment of the cognitive and functional symptoms associated with Alzheimer's disease in individuals diagnosed with mild to moderate Alzheimer’s and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and optogenetics pioneer Ed Boyden at MIT. Cognito Therapeutics is based in Cambridge, MA. For more information, please visit Follow us on Twitter at @cognitotx.

About the Digital Medicine Society

The Digital Medicine Society (DiMe) is the professional society serving the digital medicine community, driving scientific progress and broad acceptance of digital medicine to enhance public health. At DiMe, our commitment to fully integrating experts from all of the disciplines comprising digital medicine is unwavering. From regulators to white-hat hackers, ethicists to engineers, and clinicians to citizen scientists, we are proud to welcome all experts committed to ensuring that digital medicine realizes its full potential to improve human health.


Media Contact
Carla Jacobs English

Cognito Therapeutics
Kimberly Ha
KKH Advisors


Source: Cognito Therapeutics

Back to news